Ewing's sarcoma is a highly malignant musculoskeletal tumor composed of small round cells. Although important results have been achieved with surgery associated with chemotherapy, recurrent disease is still a major problem. In order to define new prognostic factors useful for therapeutic decision-making, we conducted a study on 38 Ewing's sarcoma samples in which c-myc oncogene expression and Ki67 proliferation index were correlated with clinical outcome.
Methods and Study Design
Nineteen patients developed metastases during follow-up and 10 of these patients died. C-myc and Ki67 protein expression was evaluated by immunohistochemistry performed on 5 μm formalin-fixed and paraffin-embedded sections, while the c-myc mRNA transcript was localized using in situ hybridization.
Results
A statistically positive correlation was found between c-myc protein and Ki67 (P = 0.001) and c-myc mRNA and Ki67 expression (P = 0.047). The 38 patients were divided into two groups using as the cutoff 50% of Ki67-positive cells. The disease-free survival and overall survival estimates were 68% and 90%, respectively, in the group of patients with a percentage of Ki67-positive cells <50%, and 25% and 50%, respectively, in the group with a percentage of Ki67-positive cells ≥50%. The difference between the survival curves was statistically significant (P <0.05 and P <0.01). Furthermore, relapsed patients had a high and uniform expression of c-myc protein and mRNA compared to disease-free patients.
Conclusion
These results suggest a possible role of the c-myc oncogene and Ki67 antigen in the malignant progression of Ewing's sarcoma.
BarriosC., CastresanaJ.S., RuizJ., KreicbergsA.: Amplification of c-myc oncogene and absence of c-Ha-ras point mutations in human bone sarcomas.J. Orthop. Res., 11: 556–563, 1993.
2.
BarriosC., CastresanaJ.S., KreicbergsA.: Clinicopathologic correlations and short-term prognosis in musculoskeletal sarcoma with c-myc oncogene amplification.Am. J. Clin. Oncol., 17: 273–276, 1994.
3.
BarriosH., CastresanaJ.S., RuizJ., KreicbergsA.: Amplification of the c-myc proto-oncogene in soft tissue sarcomas.Oncology, 51: 13–17, 1994.
4.
BarnardM.J., HallP.A., LemoineN.R., KadarN.: Proliferative index in breast carcinoma determined in situ by Ki-67 immunostaining and its relationship to clinical and pathological variables.J. Pathol., 152: 287–295, 1987.
5.
BlackwoodE.M., EisemanJ.K.: Max: an helix-loop-helix zipper protein that forms a sequence-specific DNA binding complex with myc.Science, 250: 1149–1151, 1991.
6.
CampanacciM.: Tumors of the soft tissues. In: Bone and soft tissue tumors, GaggiA. (Ed.), pp 841–1060, Springer-Verlag, Vienna, New York, 1990.
7.
CavazzanaA., MiserJ., JeffersonJ., TricheT.: Experimental evidence for a neural origin of Ewing's sarcoma of bone.Am. J. Pathol., 127: 507–518, 1987.
8.
CavazzanaA., MagnaniM., RossR.: Ewing's sarcoma is an undifferentiated neuroectodermal tumor.Prog. Clin. Biol. Res., 271: 577–583, 1988.
9.
ChristineF., StephensonD., JuliaA., BridgeM., SandbergA.: Cytogenetic and pathologic aspects of Ewing's sarcoma and neuroectodermal tumors.Hum. Pathol., 23: 1270–1277, 1992.
10.
CollinsS., GroudineM.: Amplification of endogenous mycrelated DNA sequences in a human myeloid leukaemia cell line.Nature, 298: 679–681, 1982.
11.
Dalla-FaveraR., Wong-StaalF., GalloR.C.: Oncogene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patients.Nature, 229: 61–63, 1982.
12.
FellingerE., Garin-ChesaP., TricheT., HuvosA., RettigW.: Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32.Am. J. Pathol., 139: 317–325, 1991.
13.
GamberiG., BenassiM., FerrariC., RagazziniP., SollazzoM., MolendiniL., SangiorgiL., PicciP.: Additional methods of diagnosis in the histopathology of the musculoskeletal system.Chir. Org. Mov., LXXX: 417–426, 1995.
HallP.A., RichardsM.A., GregoryW.M., D'ArdenneA.J., ListerT.A., StansfeldA.G.: The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma.J. Pathol., 154: 223–235, 1988.
16.
HamelP., GillR., PhillipsR., GallieB.: Transcriptional repression of the E2-containing promoters EIIaE, c-myc, and RB1 by product of the RB1 gene.Mol. Cell. Biol., 12: 3431–3438, 1992.
KellyK., CochranB., StilesC., LederP.: Cell specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor.Cell, 35: 603–610, 1983.
KroeseM., RutgersD., WilsI., Van UnnikJ., RohollP.: The relevance of the DNA index and proliferation rate in the grading of benign and malignant soft tissue tumors.Cancer, 65: 1783–1788, 1990.
21.
LadanyiM., HeinemannF., HuvosA., RaoP., ChenQ., JhanwarS.: Neural differentiation in small round cell tumors of bone and soft tissue with the translocation t (11;22) (q24;q12).Hum. Pathol., 21: 1245–1251, 1990.
22.
Liombart-BoschA., LacombeM., ContessoG.: Small round cell sarcoma of bone mimicking atypical Ewing's sarcoma with neuroectodermal features.Cancer, 60: 1570–1582, 1987.
23.
MeyerJ.: Growth and cell kinetics measurements in human tumors.Pathol. Ann., 16: 53–80, 1981.
24.
NevinsJ.R.: E2F: a link between the RB tumor suppressor protein and viral oncoproteins.Science, 258: 424–429, 1992.
25.
O'ConnorM.I., PritchardD.J.: Ewing's sarcoma.Prognostic factors, disease control, and the reemerging role of surgical treatment. Clin. Orthop., 262: 78–87, 1991.
26.
PavelicZ., PavelicL., LowerE., GapanyM., GapanyS., BarkerE.: C-myc, c-erbB2 and Ki67 expression in normal breast tissue and in invasive and non invasive breast carcinoma.Cancer Res., 52: 2597–2602, 1992.
27.
PicciP., BohlingT., BacciG., FerrariS., SangiorgiL., MercuriM., RuggieriP., ManfriniM., FerraroA., CasadeiR., BenassiM., ManciniA., RositoP., CazzolaA., BarbieriE., TienghiA., Brach del PreverA., CornandoneA., BacchiniP., BertoniF.: Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities.J. Clin. Oncol., 15: 1553–1559, 1997.
28.
QuinnC., WrightN.: The clinical assessment of proliferation and growth in human tumors: evaluation of methods and applications as prognostic variable.J. Pathol., 160: 93–102, 1990.
29.
SheinessD., BishopJ.M.: DNA and RNA from uninfected vertebrate cells contain nucleotide sequences related to the putative transforming gene of avian myelocytomatosis virus.J. Virol., 31: 465–475, 1987.
30.
ShinD.M., GuptaV., DonnerL., ChawlaS., BenjaminR., GuttermanJ., BlickM.: Abberant oncogene expression in uncultured human sarcoma and melanoma.Anticancer Res., 7: 1117–1123, 1987.
31.
SilvestriniR., DaidoneM., CostaA.: Cell kinetic of solid tumors with time and its clinical implication.Tumori, 75: 367–372, 1989.
32.
TatosyanA.G., GaletzkiS.A., KisseljovaN.P.: Oncogene expression in human tumors.Int. J. Cancer, 35: 731–736, 1985.
33.
TricheT., CavazzanaA.: Round cell tumor of bone. In: Bone tumors, UnniK.K. (Ed.), Churchill Livingstone, New York, 1988.
34.
Turc-CarelC., PhilipI., BergerM.: Chromosome study of Ewing's sarcoma (ES) cell lines: Consistency of reciprocal translocation t(11;22) (q24C2).Cancer Genet. Cytogenet., 12: 1–19, 1984.
35.
UshigomeS., ShimodaT., TakakiK., NikaidoT., TakakuwaT., IshikawaE., SpjutH.: Immunocytochemical and ultrastructural studies of the histogenesis of Ewing's sarcoma and putatively related tumors.Cancer, 64: 52–62, 1989.
36.
UedaT., AozasaK., TsujimotoM., OhsawaM., UchidaA., AokiY.: Prognostic significance of Ki67 reactivity in soft tissue sarcomas.Cancer, 63: 1607–1611, 1989.
37.
Whang-PengJ., TricheT., KnutsenT.: Cytogenetic characterization of selected small round cell tumors of childhood.Cancer Genet. Cytogenet., 21: 185–208, 1986.
38.
ZutterM., KrigmanH., SantoroS.: Altered integrin expression in adenocarcinoma of the breast.Am. J. Pathol., 142: 1439–1448, 1993.
